Please login to the form below
Immune Design
This page shows the latest Immune Design news and features for those working in and with pharma, biotech and healthcare.
Merck bulks up in cancer with $2.2bn Peloton buy
It is the second pipeline-boosting deal for Merck in three months, coming after it paid $300m for cancer vaccine developer Immune Design.
Latest news
-
Merck & Co to buy IO specialists Immune Design for $300m
US giant looks to next generation technology. Immunotherapy leader Merck &Co/MSD is to acquire a vaccine specialist firm Immune Design for $300m. ... last went shopping for a new bolt-on technology. Immune Design is a late-stage immunotherapy company
-
Genital herpes vaccine candidate promising in phase II
Other companies working on HSV-2 vaccines include Sanofi/Immune Design, Agenus, Tomegavax and Australian company Admedus, which has also just reported preliminary phase II data on its candidate.
-
Vical's genital herpes vaccine flunks trial
Both a monovalent and a bivalent version of the vaccine against Herpes simplex virus type 2 (HSV-2) - which are formulated with Vical's adjuvant Vaxfectin to boost immune responses - failed ... outbreaks. Last year, Sanofi set up an alliance with Immune
-
Sanofi to work with Immune Design on herpes vaccine
Sanofi has joined forces with US biotech Immune Design to accelerate development of the first therapeutic vaccine against genital herpes. ... Sanofi vaccines division Sanofi Pasteur and Immune Design both have candidates in early-stage testing but have
-
Merck Serono enters anti-PD-1 fray
MSB0010718C blocks the interaction of PD-L1 with its receptor PD-1 and may have the potential to restore effective anti-tumour immune responses, according to Merck Serono. ... Meanwhile, OncoSec Medical which has an intratumoral immunotherapy for MCC
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Combined immunotherapies – potential and pitfalls
may guide the more rational design of clinical trials to improve immune surveillance and tumour control.”. ... Drug development is outpacing our capacity to develop biomarkers due to the complexity of the cancer immune response.
-
Deal Watch table for August 2014
183. Immune Design/ Sanofi. Licence. GLAAS discovery platform to develop therapeutics for a selected food allergy.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
- Why everyone in pharma is bending over backwards to be agile
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
